Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

More to come from PARP drugs, says biotech CEO after strikin...

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.

AZ gets China nod for Tagrisso in first-line lung cancer

The top pharma companies by revenue 2018

Could phase 3 trial win save AZ's troubled Lupus drug?

AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a late-stage study for a potential lupus drug that looked dead and buried after a major trial

FDA fast-tracks AZ's Farxiga in potential new CKD indication

The FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and prevent cardiovascular death and renal death in patients with chronic kidney